A Phase II Study Testing the Safety and Activity of AGS-003 as an Immunotherapeutic in Subjects With Newly Diagnosed Advanced Stage Renal Cell Carcinoma in Combination With Sunitinib.

Trial Profile

A Phase II Study Testing the Safety and Activity of AGS-003 as an Immunotherapeutic in Subjects With Newly Diagnosed Advanced Stage Renal Cell Carcinoma in Combination With Sunitinib.

Completed
Phase of Trial: Phase II

Latest Information Update: 23 Apr 2015

At a glance

  • Drugs Rocapuldencel-T (Primary) ; Sunitinib
  • Indications Renal cell carcinoma
  • Focus Therapeutic Use
  • Sponsors Argos Therapeutics Inc
  • Most Recent Events

    • 21 Apr 2015 Results published in the Journal for ImmunoTherapy of Cancer, according to a Argos Therapeutics Inc media release.
    • 18 Sep 2014 Results published in Argos Therapeutics media release.
    • 14 Feb 2013 Results will be presented at the 2013 American Society of Clinical Oncology (ASCO) Genitourinary Cancers Symposium according to an Argos Therapeutics media release. Results were also briefly summarised in the media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top